70 results about "SOD1" patented technology

Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.

Though copper is elevated in the tumor tissue and plasma of patients with various malignancies, the molecular targets for copper binding agents in angiogenesis and tumor progression remain poorly understood. It is disclosed that one anti-angiogenic target for the copper binding agent tetrathiomolybdate is intracellular CuZn-superoxide dismutase (SOD1). A second generation tetrathiomolybdate analog, ATN-224, inhibits endothelial cell (EC) proliferation in vitro, binds to SOD1 and inhibits its activity without displacing bound copper ATN-224 can accumulate in ECs and inhibit CuZnSOD activity with an IC₅₀ similar to the IC₅₀ for EC proliferation, resulting in increased generation of intracellular reactive oxygen species. Inhibition of EC proliferation by ATN-224 in vitro is substantially reversed by a synthetic porphyrin SOD mimetic. Similar results were observed in vivo, where inhibition of angiogenesis by ATN-224 in a Matrigel plug model was also reversed by MnTBAP. Thus, a distinct molecular target for copper depletion therapy has been identified and SOD1 is now validated as a target for anti-angiogenesis. Methods for screening, or designing, such SOD1 inhibitors for use as angiogenesis inhibitors and anti-cancer agents are disclosed.

The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention.

The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.

A stabilized superoxide dismutase (SOD1) analogue, wherein the side chains of two amino acids on two different SOD1 monomers are connected is provided. A method of producing a stabilized superoxide disumutase (SOD1) analogue comprises reacting a first SOD1 monomer, a second SOD1 monomer, and a cross-linker.

The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.

The invention discloses a custom customization method of an anti-aging skincare product. The custom customization method comprises the following steps: step 1, collecting user cell samples; step 2, extracting mRNA in the cell samples; step 3, performing reverse transcription for the mRNA to synthesize cDNA; step 4, detecting polymorphism of aging-related genes in cDNA and expression of corresponding cDNA, wherein the aging-related gene contains at least one of MMP9, NQ01, SOD1 and FOXO4; and step 5, judging the anti-aging capacity according to the gene polymorphism and the corresponding cDNA expression, selecting anti-aging skincare product components and use amount according to the anti-aging capacity, and preparing the appropriate anti-aging skincare product. The anti-aging capacity of different users is acquired by measuring the expression of the aging-related gene, and the appropriate anti-aging skincare product is prepared according to the specific anti-aging capacity of the user.

Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.

The invention discloses a method for cultivating a resistant plant, and special protein and gene thereof. GhSOD1 protein provided by the invention is protein described as (a) or (b): (a) protein formed by 85th to 236th amino acid residues from N end of a sequence 3; and (b) protein which is derived from the protein of the sequence 3 and is obtained by processing the protein described in (a) by substituting and/or deleting and/or adding one or multiple amino acid residues related to plant resistance. GhCAT1 protein provided by the invention is protein described as (c) or (d): (c) protein formed by 85th to 576th amino acid residues from N end of a sequence 4; and (d) protein formed by 85th to 236th amino acid residues from N end of a sequence 3; and (b) protein which is derived from the protein of the sequence 4 and is obtained by processing the protein described in (a) by substituting and/or deleting and/or adding one or multiple amino acid residues related to plant resistance. According to the method, SOD1 gene and CAT1 gene of cotton are cloned, also the chloroplast signal peptide sequence of arabidopis thaliana THI1 gene is utilized for constructing chimeric gene, and the chimeric gene is overexpressed in cotton, so that the transgenic cotton with high salt resistance, drought resistance and disease resistance is cultivated. The technical scheme provided by the invention has important meaning on plant stress resistance, disease resistance and breeding.

The invention discloses protein markers assisting diagnosis of severe secondary pulmonary tuberculosis. The invention provides applications of a product for detecting SOD1 protein, a product for detecting S100A9 protein, a product for detecting ORM2 protein and a product for detecting IL1F6 protein in preparation of a kit used for assisting diagnosis of severe secondary pulmonary tuberculosis. The four protein markers (S100A9, ORM2, IL1F6 and SOD1) assisting diagnosis of the severe secondary pulmonary tuberculosis are found, and a model for assisting diagnosis of the severe secondary pulmonary tuberculosis by utilizing the four protein markers is built. The protein markers provide basis for further explanation of developing and aggravating mechanisms of the secondary pulmonary tuberculosis, provide a novel method and novel indexes for disease development, aggravation early warning, and forecast evaluation, lays a foundation for reasonable treatment and cure of the severe secondary pulmonary tuberculosis, and provides technical supports for reducing the death rate of pulmonary tuberculosis.

The invention relates to a new use of a porcine SOD1 gene in PRRS (Porcine Reproductive and Respiratory Syndrome) virus resistance and specifically relates to application of the porcine SOD1 gene in PRRS virus resistance. The duplication of the PRRS virus in cells is inhibited by virtue of overexpression of the CDS sequence of the porcine SOD1 gene in the cells. The invention also provides a method for breeding an anti-PRRS virus transgenic pig, and a method for screening anti-PRRS virus pigs according to the expression quantity of the SOD1 gene.

Cells within liver tumour mass comprise a unique set of proteins/tumour antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumour. The presence of tumour antigens couples the production of auto-antibodies against these tumour antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumour antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26, to complement the conventional diagnostic methods.

The invention discloses a kit for detecting gastric cancer risk gene, which comprises a detection reagent for detecting one or more of 11 mononucleotide polymorphism sites in 9 genes, concretely for detecting COX-2 gene rs5273 and rs20417 mutation; IL-10 gene rs1800896 mutation; P53 gene rs1042522 mutation; PARP-1 gene rs1136410 and rs3219145 mutation; PLCE1 gene rs2274223 mutation; RKAA1 gene rs13361707 mutation; PSCA gene rs2294008 mutation; SOD1 gene Rs4998557 mutation; and SOD2 gene rs4880 mutation. The kit can be used for detecting a plurality of mutant genes in a sample of an individualto-be-tested, the occurrence of gastric cancer can be monitored or diagnosed at an early stage, and a reference for clinical diagnosis and treatment can be provided.